Bavarian Nordic (OTCPK:BVNRY) has received FDA approval for its vaccine Vimkunya for the prevention of chikungunya. The virus-like particle, or VLP, vaccine is approved for people aged 12 and older.

First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention ...

First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger travelers.On track for commercial launch in the U.S. in the ...

Louisiana Surgeon General Ralph Abraham sent a directive to state health workers Thursday ending long-standing mass ...

Feb. 5, 2025 — Researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful ...

The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...

The narrative is false that the COVID vaccine was rushed and not properly tested. It and other vaccines are safe and ...

There are no approved vaccines or treatments for Sudan virus disease, which has a 40–70% fatality rate. To curb the ongoing outbreak, Uganda has deployed—under a clinical trial setting—a vaccine ...

A 12-year-old Atlanta girl has turned to Cleveland researchers for treatment of her Ewing Sarcoma, and the hope a ...

As a deliverable, the advancement in development of an urgently needed new medical intervention, a therapeutic vaccine for Chagas disease, one of the most important neglected tropical diseases in ...

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old.The virus-like particle (VLP) single-dose chikungunya ...

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old.The virus-like particle (VLP) single-dose chikungunya vaccine is expected to launch in key European markets in ...